文献速递乳腺癌

中危乳腺癌乳房切除术后放疗的生活质量:SUPREMO试验2年随访

Quality of life after postmastectomy radiotherapy in patients with intermediate-risk breast cancer (SUPREMO): 2-year follow-up results of a randomised controlled trial.
PubMed 文献 · Lancet Oncol · 2018-10-15

SUPREMO试验将中危乳腺癌乳房切除术后患者随机分为胸壁放疗组与不放疗组,比较生活质量(预设次要终点)。手臂与肩部症状、体像、疲乏、总体生活质量、躯体功能及焦虑抑郁无差异。

要点

  • 中危乳腺癌乳房切除术后放疗在2年内胸壁症状略重于不放疗,组间差异小。
  • 手臂和肩部症状、体像、疲乏、总体生活质量、躯体功能、焦虑抑郁两组无差异。
  • 两组胸壁症状在第1至2年间均有改善,结果可用于医患共同决策。

核心结论

  • 乳房切除术后放疗较不放疗增加2年内胸壁局部症状,但组间差异小。
  • 手臂和肩部症状、体像、疲乏、总体生活质量、躯体功能及焦虑抑郁评分两组无差异。
  • 需等待10年总生存(试验主要终点)结果以指导临床决策。

研究设计与样本

  • SUPREMO为开放标签、国际、平行组、随机对照试验,按1:1随机分配至胸壁放疗或不放疗。
  • 入组18岁及以上中危乳腺癌患者,中危定义为pT1-2N1、pT3N0或pT2N0且III级或伴淋巴血管侵犯,均已行乳房切除术。
  • 放疗方案为50 Gy分25次,或生物学等效的45 Gy分20次或40 Gy分15次。
  • 2006年8月4日至2013年4月29日国际入组1688例,放疗组853例、不放疗组835例。
  • 生活质量亚组来自111个英国中心的1258例患者中989例(79%)同意参与,947例(96%)返回基线问卷纳入分析(放疗组471例、不放疗组476例)。

主要发现

  • 手臂和肩部症状、体像、疲乏、总体生活质量、躯体功能、焦虑抑郁评分两组均未见差异。

关键数值与推荐

  • 生活质量亚组预设主要结局为总体生活质量、疲乏、躯体功能、胸壁症状、肩臂症状、体像、焦虑和抑郁。
  • 生活质量问卷包括EORTC QLQ-C30、QLQ-BR23、体像量表、医院焦虑抑郁量表(HADS)和EQ-5D-3L。
  • 分析采用意向性治疗原则和重复混合效应模型。

临床怎么用

  • 对中危乳腺癌乳房切除术后患者,放疗对2年内生活质量影响有限,主要表现为胸壁症状轻度增加。
  • 可与患者共享决策时告知:放疗组胸壁症状略重但差异小,其他生活质量维度无差异。
  • 最终放疗决策仍需结合尚未公布的10年总生存主要终点结果。

局限性

  • 本文仅报告2年生活质量结果,生存主要终点尚未报告。
  • 生活质量亚组仅纳入英国患者,为整体试验的部分人群。
  • 试验为开放标签,患者和研究者未设盲。
  • 随机分组未设区组长度固定,采用可变长度区组分层随机。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Postmastectomy radiotherapy in patients with four or more positive axillary nodes reduces breast cancer mortality, but its role in patients with one to three involved nodes is controversial. We assessed the effects of postmastectomy radiotherapy on quality of life (QOL) in women with intermediate-risk breast cancer. METHODS: SUPREMO is an open-label, international, parallel-group, randomised, controlled trial. Women aged 18 years or older with intermediate-risk breast cancer (defined as pT1-2N1; pT3N0; or pT2N0 if also grade III or with lymphovascular invasion) who had undergone mastectomy and, if node positive, axillary surgery, were randomly assigned (1:1) to receive chest wall radiotherapy (50 Gy in 25 fractions or a radiobiologically equivalent dose of 45 Gy in 20 fractions or 40 Gy in 15 fractions) or no radiotherapy. Randomisation was done with permuted blocks of varying block length, and stratified by centre, without masking of patients or investigators. The primary endpoint is 10-year overall survival. Here, we present 2-year results of QOL (a prespecified secondary endpoint). The QOL substudy, open to all UK patients, consists of questionnaires (European Organisation for Research and Treatment of Cancer QLQ-C30 and QLQ-BR23, Body Image Scale, Hospital Anxiety and Depression Scale [HADS], and EQ-5D-3L) completed before randomisation, and at 1, 2, 5, and 10 years. The prespecified primary outcomes within this QOL substudy were global QOL, fatigue, physical function, chest wall symptoms, shoulder and arm symptoms, body image, and anxiety and depression. Data were analysed by intention to treat, using repeated mixed-effects methods. This trial is registered with the ISRCTN registry, number ISRCTN61145589. FINDINGS: Between Aug 4, 2006, and April 29, 2013, 1688 patients were enrolled internationally and randomly assigned to receive chest wall radiotherapy (n=853) or not (n=835). 989 (79%) of 1258 patients from 111 UK centres consented to participate in the QOL substudy (487 in the radiotherapy group and 502 in the no radiotherapy group), of whom 947 (96%) returned the baseline questionnaires and were included in the analysis (radiotherapy, n=471; no radiotherapy, n=476). At up to 2 years, chest wall symptoms were worse in the radiotherapy group than in the no radiotherapy group (mean score 14·1 [SD 15·8] in the radiotherapy group vs 11·6 [14·6] in the no radiotherapy group; effect estimate 2·17, 95% CI 0·40-3·94; p=0·016); however, there was an improvement in both groups between years 1 and 2 (visit effect -1·34, 95% CI -2·36 to -0·31; p=0·010). No differences were seen between treatment groups in arm and shoulder symptoms, body image, fatigue, overall QOL, physical function, or anxiety or depression scores. INTERPRETATION: Postmastectomy radiotherapy led to more local (chest wall) symptoms up to 2 years postrandomisation compared with no radiotherapy, but the difference between groups was small. These data will inform shared decision making while we await survival (trial primary endpoint) results. FUNDING: Medical Research Council, European Organisation for Research and Treatment of Cancer, Cancer Australia, Dutch Cancer Society, Trustees of Hong Kong and Shanghai Banking Corporation.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Velikova G, Williams LJ, Willis S, et al. Quality of life after postmastectomy radiotherapy in patients with intermediate-risk breast cancer (SUPREMO): 2-year follow-up results of a randomised controlled trial. Lancet Oncol. 2018. PMID: 30337220. doi:10.1016/S1470-2045(18)30515-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。